What's behind Hims & Hers's latest 3.6% stock surge?

Traders Union
All News
Stocks
Hims & hers surges 3.61% today

Highlights

Hims & Hers Health faces a class action lawsuit over alleged improper billing and misleading privacy practices after regulatory action was filed in July 2026.
The class action process is ongoing, with a lead plaintiff appointment deadline set for November 2, 2026.
Shares of Hims & Hers are seeing short- and medium-term selling pressure, with momentum indicators negative and a forecast trading range of $27.34 to $30.14 over the next five days.

Class action accelerates after FTC lawsuit alleges billing, privacy breaches

Several law firms have announced that a class action lawsuit has been filed against Hims & Hers Health Inc following regulatory action and alleged securities law violations. On July 29, 2026, the Federal Trade Commission and state authorities filed a lawsuit in the Northern District of California, alleging improper consumer billing and misleading privacy practices. The class action process is ongoing, with a deadline for lead plaintiff appointment set for November 2, 2026.

Anton Kharitonov, expert at Traders Union, sees recent gains in Hims & Hers Health Inc as a technical rebound within a broader decline. He points to ongoing regulatory action and class action litigation as heavy overhangs on sentiment and fundamentals. Short-term technicals remain bearish, and momentum signals are negative despite a volatile uptick. Kharitonov is skeptical about any sustained recovery, noting resistance zones remain intact with the stock under key moving averages. "I see limited upside, with unresolved legal risk likely to drive further weakness toward support at $28.03 or below."

Viktoras Karapetjanc, expert at Traders Union, maintains a constructive outlook despite recent market turbulence in HIMS. He views the underlying bullish structure as preserved with prices holding above the 200-day average. The current legal challenges introduce temporary uncertainty, but he believes the long-term trend supports eventual recovery. Karapetjanc remains confident there are multiple opportunities for growth if price breaks through $28.89 resistance. "I expect further upside once current volatility subsides and the company regains investor confidence."

Jainam Mehta, market strategist, notes the gap higher and resulting divergence between short-term indicators and price action. He sees sideways consolidation as the most probable scenario near $28. If legal-driven volatility persists, tactical traders may look for contrarian entries around support levels. "A decisive move above $28.89 could flip the near-term bias, but risk remains elevated either way."

Short-term selling pressure persists despite buyers driving intraday bounce

Hims & Hers is trading below its 20-day and 50-day moving averages ($29.23 and $30.34), but remains above the 200-day moving average at $28.03, reflecting short- and medium-term selling pressure, while the long-term trend stays constructive. Near-term resistance sits at $28.89, with support at the 200-day average ($28.03) and the Ichimoku Kijun at $30.61 flagging medium-term overhead resistance. Momentum signals are negative, with the MACD at -0.89 indicating a strong sell, and a neutral ADX at 8.37. Oscillators such as RSI (45.15), CCI (-52.41), and Stochastic RSI (44.25) point to mild selling or neutral pressure. Bull/Bear Power at 0.56 marks buyers dominating intraday, suggesting a short squeeze or overbought bounce. Volatility stands at 4.33%, with prices near session highs after an upside gap, but short-term indicators diverge against today’s upward move.

Earlier, analysts noted that persistent legal risks and bearish technical signals were contributing to an uncertain and consolidation-prone outlook for Hims & Hers shares. The current analysis reaffirms this view with updated data, highlighting continued volatility and caution around the $28.89 resistance level as a key area to watch for any shift in trend.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.